Humira Patent Invalid for Obviousness Type Double Patenting
By EsqSocial Corporation 26/08/14
In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court’s finding that a second patent covering AbbVie’s Humira product is invalid under the doctrine of obviousness-type double patenting. The...
By: Foley & Lardner LLP